A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(41 sites)

United States

Research Site, Largo, Florida

Research Site, Fort Wayne, Indiana

Research Site, Omaha, Nebraska

Research Site, New York, New York

Research Site, Houston, Texas

Research Site, Puyallup, Washington

China

Research Site, Beijing

Research Site, Changsha

Research Site, Guangzhou

Research Site, Linyi

Research Site, Shandong

Research Site, Wuhan

Research Site, Zhengzhou

France

Research Site, Clermont-Ferrand

Research Site, La Roche-sur-Yon

Research Site, Montpellier

Research Site, Paris

Research Site, Pierre-Bénite

Italy

Research Site, Aviano

Research Site, Florence

Research Site, Meldola

Research Site, Milan

Research Site, Naples

Research Site, Roma

South Korea

Research Site, Bukgu

Research Site, Goyang-si

Research Site, Seoul

Spain

Research Site, A Coruña

Research Site, Barcelona

Research Site, Granada

Research Site, Madrid

Research Site, Seville

Research Site, Valencia